1 May 2012AsiaArchana Shanker

A step into the unknown: India's first compulsory licence

The licence was granted to Natco Pharma, a generic drug company, for sorafenib tosylate, a life-extending drug developed, patented and launched by Bayer Corporation. This drug is sold under the trade name of Nexavar and is used for the treatment of advanced-stage kidney and liver cancer.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Takeda’s China IP head: What pharma is still getting wrong

27 May 2026 China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.

Asia

Healthcare leads sweeping AI partnership in Singapore

20 May 2026 Backed by the country’s wider AI ambitions, Google has signed a deal to roll out healthcare, scientific research, and safety initiatives.

Asia

IndiaMart v CDSCO: A test of intermediary liability

31 March 2026 The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.

More features

Hikma v Amarin: Six takeaways from the pivotal ruling

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

Chadha & Chadha hires former Remfry & Sagar patent partner

Takeda’s China IP head: What pharma is still getting wrong

Healthcare leads sweeping AI partnership in Singapore

BMS signs $15.2bn deal with China’s top pharma company

From the courtroom: Hikma v Amarin SCOTUS oral arguments

Simmons & Simmons makes senior Asia trademark hire

A step into the unknown: India's first compulsory licence

More on this story

Editor's picks

Editor's picks

More features